Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Birkinshaw, Richard W., Gong, Jia-nan, Luo, Cindy S., Lio, Daisy, White, Christine A., Anderson, Mary Ann, Blombery, Piers, Lessene, Guillaume, Majewski, Ian J., Thijssen, Rachel, Roberts, Andrew W., Huang, David C. S., Colman, Peter M., Czabotar, Peter E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547681/
https://ncbi.nlm.nih.gov/pubmed/31160589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-10363-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados